✦ LIBER ✦

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group

✍ Scribed by Califano, Raffaele; Griffiths, Richard; Lorigan, Paul; Ashcroft, Linda; Taylor, Paul; Burt, Paul; Lee, Lip; Chittalia, Abbas; Harris, Margaret; Faivre-Finn, Corinne; Thatcher, Nick; Blackhall, Fiona

Book ID: 119320533
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 488 KB
Volume: 73
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2011.01.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-584 Single agent gemcitabine (GEM) in

P-584 Single agent gemcitabine (GEM) in performance status (PS) 2–3patients (pts) with advanced non-small cell lung cancer (NSCLC): Effect on disease-related symptoms in a multicenter phase II trial

✍ Tiseo, M.; Tognoni, A.; Carob, C.; Mencoboni, M.; Pennucci, M.; Coialbu, T.; Bre 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A phase II trial of low-dose docetaxel (

A phase II trial of low-dose docetaxel (DCT) 60 mg/m2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC)

✍ Kusaba, H; Nakamura, Y; Kunitoh, H; Sekine, I; Kubota, K; Tamura, T; Shinkai, T; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Sequential therapy with Vinorelbine foll

Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial

✍ Hirsh, Vera; Latreille, Jean; Kreisman, Harvey; Desjardins, Pierre; Ofiara, Lind 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Phase II trial of a 75-mg/m2 dose of doc

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

✍ Vincent A. Miller; James R. Rigas; Prudence A. Francis; Stefan C. Grant; Katheri 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 2 views

## Background. A prior Phase I1 study of a 100-mg/m2 dose of docetaxel conducted at the Memorial Sloan-Kettering Cancer Center (New York, NY) demonstrated a 38% response rate with grade 3 or 4 neutropenia in 76% of the patients and a grade 2 or greater rash or infusionrelated reaction in 41% and 3

Phase II trial of a 75-mg/m2 dose of doc

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Single-Agent Gefitinib in Patients with

Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial

✍ David R. Spigel; John D. Hainsworth; Emily R. Burkett; Howard A. Burris; Denise 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 519 KB